That revamp was designed to ensure the biotech had resources to deliver three key trial readouts, namely interim data from the phase 2 portion of its antibody-drug conjugate (ADC) MGC018 in prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback